Gastrointestinal adverse events of tirzepatide in the treatment of type 2 diabetes mellitus: A meta-analysis and trials sequential analysis

BACKGROUND: Tirzepatide (TZP) is a novel drug for type 2 diabetes mellitus (T2DM), but the gastrointestinal (GI) adverse events (AEs) is a limiting factor in clinical application. Therefore, this study systematically evaluated the GI AEs of TZP for T2DM. METHODS: Clinical trials of TZP for T2DM were...

Descripción completa

Detalles Bibliográficos
Autores principales: Tong, Keke, Yin, Shuang, Yu, Yunfeng, Yang, Xinyu, Hu, Gang, Zhang, Fei, Liu, Zhenjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
4300
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615484/
https://www.ncbi.nlm.nih.gov/pubmed/37904345
http://dx.doi.org/10.1097/MD.0000000000035488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10615484/
https://www.ncbi.nlm.nih.gov/pubmed/37904345
http://dx.doi.org/10.1097/MD.0000000000035488

Ejemplares similares